[HTML][HTML] 长江资讯网admin 2019-03-12 16: 52
JBW OSAKA - changjiangzx.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] 每日热点网-国际综合资讯平台admin 2019-03-12 16: 51
JBW OSAKA - mrrdw.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] 每日热点网-国际综合资讯平台admin 2019-09-26 17: 48
JBW OSAKA - mrrdw.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced further results from the VARSITY study, which demonstrated the superiority of …
announced further results from the VARSITY study, which demonstrated the superiority of …
[HTML][HTML] 作者: CN-INFO 责任编辑: 文传商讯2019-03-11 10: 11: 00 来源: 文传商讯关键字: null
JBW OSAKA - cbinews.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[HTML][HTML] 长江资讯网admin 2019-07-30 16: 13
JBW OSAKA - changjiangzx.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety …
announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety …
[HTML][HTML] Vedolizumab (Entyvio (R)) Ac
JBW OSAKA - jiangximinsheng.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
[引用][C] Vedolizumab (Entyvio®) Achieves Superior Rates of Clinical Remission vs. Adalimumab (Humira®) in First Ever Head-to-Head Biologic Clinical Study in …
JBW OSAKA - 2019 - finet.hk
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
announced results from the Phase 3b head-to-head VARSITY study which demonstrated …
S288 Clinical Effectiveness of Vedolizumab in Chinese Ulcerative Colitis Patients: Results From the VALUE Study
B Chen, L Xie, Y Liu, M Chen - … journal of the American College of …, 2023 - journals.lww.com
Methods: VALUE study is a prospective, multicenter, single-armed observational study to
evaluate the safety and effectiveness of VDZ in the Chinese population, with a study sample …
evaluate the safety and effectiveness of VDZ in the Chinese population, with a study sample …
[HTML][HTML] First Head-to-Head Bio
JBW OSAKA - jiangximinsheng.com
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK)(“Takeda”) today
announced further results from the VARSITY study, which demonstrated the superiority of …
announced further results from the VARSITY study, which demonstrated the superiority of …
[HTML][HTML] Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
K Huang, J Liu, W Xia, C Tian, L Yao, Q Cao… - Frontiers in …, 2023 - frontiersin.org
Introduction: The effectiveness and safety of vedolizumab (VDZ) against ulcerative colitis
(UC) have been validated in several randomized controlled trials and real-world studies in …
(UC) have been validated in several randomized controlled trials and real-world studies in …